Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond.
novel agents
relapsed and refractory multiple myeloma
renal insufficiency
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Oct 2021
09 Oct 2021
Historique:
received:
19
08
2021
revised:
19
09
2021
accepted:
29
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Renal insufficiency is one of the most frequent complications in multiple myeloma. The incidence of renal insufficiency in patients with multiple myeloma ranges from 20% to 50%. Renal impairment in patients with multiple myeloma results primarily from the toxic effects of monoclonal light chains on the kidneys. Dehydration, hypercalcemia, hyperuricemia, the application of nephrotoxic NSARs, antibiotics, contrast agents, etc., all play a major role in the deterioration of renal function in patients with multiple myeloma. The diagnosis and treatment of these patients use an interdisciplinary approach in consultation with hematologist-oncologists, radiologists, nephrologists and intensive care specialists. Using new drugs in the treatment of patients with refractory/relapsed multiple myeloma and renal insufficiency markedly improves progression-free survival and overall survival in these patients. New drugs have helped to widen the treatment options available for patients with renal impairment and refractory/relapsed multiple myeloma, since dose adjustments are unnecessary with carfilzomib as well as with panobinostat, elotuzumab, pomalidomide or daratumumab in patients with renal impairment. Several new substances for the treatment of refractory/relapsed multiple myeloma have been approved in the meantime, including belantamab mafodotin, selinexor, melflufen, venetoclax, CAR T-cell therapy and checkpoint inhibitors. Ongoing studies are investigating their administration in patients with renal impairment.
Sections du résumé
BACKGROUND
BACKGROUND
Renal insufficiency is one of the most frequent complications in multiple myeloma. The incidence of renal insufficiency in patients with multiple myeloma ranges from 20% to 50%. Renal impairment in patients with multiple myeloma results primarily from the toxic effects of monoclonal light chains on the kidneys. Dehydration, hypercalcemia, hyperuricemia, the application of nephrotoxic NSARs, antibiotics, contrast agents, etc., all play a major role in the deterioration of renal function in patients with multiple myeloma. The diagnosis and treatment of these patients use an interdisciplinary approach in consultation with hematologist-oncologists, radiologists, nephrologists and intensive care specialists. Using new drugs in the treatment of patients with refractory/relapsed multiple myeloma and renal insufficiency markedly improves progression-free survival and overall survival in these patients.
CONCLUSIONS
CONCLUSIONS
New drugs have helped to widen the treatment options available for patients with renal impairment and refractory/relapsed multiple myeloma, since dose adjustments are unnecessary with carfilzomib as well as with panobinostat, elotuzumab, pomalidomide or daratumumab in patients with renal impairment. Several new substances for the treatment of refractory/relapsed multiple myeloma have been approved in the meantime, including belantamab mafodotin, selinexor, melflufen, venetoclax, CAR T-cell therapy and checkpoint inhibitors. Ongoing studies are investigating their administration in patients with renal impairment.
Identifiants
pubmed: 34680184
pii: cancers13205036
doi: 10.3390/cancers13205036
pmc: PMC8533858
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Leukemia. 2008 Apr;22(4):842-9
pubmed: 18200040
Leukemia. 2008 Aug;22(8):1485-93
pubmed: 18528426
Oncogene. 2007 Apr 5;26(16):2374-80
pubmed: 17016430
Blood. 2011 Jun 23;117(25):6856-65
pubmed: 21543761
Oncotarget. 2017 Jun 13;8(24):39805-39817
pubmed: 27458170
Leukemia. 2018 Feb;32(2):252-262
pubmed: 29257139
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Eur J Haematol. 2004 Aug;73(2):98-103
pubmed: 15245508
Leukemia. 2013 Aug;27(8):1707-14
pubmed: 23364621
Blood. 2019 Jan 10;133(2):147-155
pubmed: 30478094
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Nat Rev Clin Oncol. 2017 Jul;14(7):417-433
pubmed: 28117417
Cancer Cell. 2005 Nov;8(5):407-19
pubmed: 16286248
Blood Cancer J. 2018 Nov 9;8(11):109
pubmed: 30413684
Blood. 2018 Feb 22;131(8):855-863
pubmed: 29203585
Blood. 2016 Jun 23;127(25):3225-36
pubmed: 27127303
Oncotarget. 2017 Jun 8;8(39):66641-66655
pubmed: 29029544
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Immunotherapy. 2015;7(11):1187-99
pubmed: 26370838
Blood Res. 2020 Jul 31;55(S1):S43-S53
pubmed: 32719176
Leukemia. 2021 Feb;35(2):562-572
pubmed: 32444867
Haematologica. 2020 Jan;105(1):e37-e40
pubmed: 31004032
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Br J Clin Pharmacol. 2010 May;69(5):484-97
pubmed: 20573084
Lab Invest. 1995 Dec;73(6):810-7
pubmed: 8558842
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Future Oncol. 2020 Jan;16(2):4347-4358
pubmed: 31833394
Am J Hematol. 2015 Nov;90(11):981-5
pubmed: 26214732
Nat Immunol. 2000 Sep;1(3):252-6
pubmed: 10973284
Blood. 2016 Feb 11;127(6):713-21
pubmed: 26631116
Blood. 2018 Dec 13;132(24):2546-2554
pubmed: 30352784
Lancet Haematol. 2019 Sep;6(9):e448-e458
pubmed: 31327689
Clin Cancer Res. 2013 Jun 1;19(11):3019-31
pubmed: 23584492
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
ESMO Open. 2019 Sep 8;4(5):e000570
pubmed: 31555488
Oncologist. 2018 May;23(5):631-636
pubmed: 29192015
BMJ Case Rep. 2016 Sep 22;2016:
pubmed: 27659911
N Engl J Med. 2018 Nov 8;379(19):1791-1795
pubmed: 30403935
Curr Cancer Drug Targets. 2011 Mar;11(3):254-84
pubmed: 21247382
Anticancer Res. 2016 Jun;36(6):2889-92
pubmed: 27272801
Leukemia. 2019 Sep;33(9):2266-2275
pubmed: 30858549
Lancet Oncol. 2021 Mar;22(3):e105-e118
pubmed: 33662288
Immunol Rev. 2015 Jan;263(1):210-23
pubmed: 25510279
Nat Rev Nephrol. 2011 Nov 01;8(1):43-51
pubmed: 22045243
Case Reports Immunol. 2018 Jun 13;2018:1623957
pubmed: 30009063
Cancer Sci. 2017 Jun;108(6):1109-1118
pubmed: 28301076
J Pharm Pharmacol. 2003 Dec;55(12):1701-6
pubmed: 14738599
Expert Rev Hematol. 2014 Dec;7(6):719-31
pubmed: 25265911
Br J Haematol. 2016 Sep;174(5):748-59
pubmed: 27196567
J Clin Oncol. 2012 Aug 20;30(24):2946-55
pubmed: 22802322
Mol Cancer Ther. 2016 May;15(5):1132-44
pubmed: 26939706
Br J Haematol. 2020 Feb;188(4):501-510
pubmed: 31588567
Clin Cancer Res. 2012 Apr 15;18(8):2145-63
pubmed: 22328563
Cancer J. 2019 Jan/Feb;25(1):45-53
pubmed: 30694859
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38
pubmed: 26795075
Lancet Oncol. 2020 Dec;21(12):1630-1642
pubmed: 33129376
Cell. 1994 Sep 9;78(5):773-85
pubmed: 8087845
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
Expert Opin Pharmacother. 2013 Aug;14(11):1477-95
pubmed: 23705905
Leukemia. 2016 May;30(5):1086-93
pubmed: 26707935
Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):191-6
pubmed: 22341857
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Br J Haematol. 2021 May;193(4):e33-e36
pubmed: 33748953
Haematologica. 2007 Oct;92(10):1411-4
pubmed: 17768111
Biochem Pharmacol. 2019 Oct;168:412-428
pubmed: 31325448
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Blood. 2010 Sep 30;116(13):2286-94
pubmed: 20460501
J Cancer Res Clin Oncol. 2021 Jan;147(1):205-212
pubmed: 32683487
Blood. 2016 May 26;127(21):2561-8
pubmed: 26932802
N Engl J Med. 2018 Nov 8;379(19):1811-1822
pubmed: 30403938
J Clin Oncol. 2021 Mar 1;39(7):757-767
pubmed: 33296242
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
J Clin Oncol. 2018 Jul 10;36(20):2035-2043
pubmed: 29394124
J Clin Oncol. 2016 May 1;34(13):1544-57
pubmed: 26976420
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Lancet Haematol. 2019 Sep;6(9):e459-e469
pubmed: 31327687
Blood Cancer J. 2018 Aug 29;8(9):86
pubmed: 30190454
Leukemia. 2020 Apr;34(4):1197-1201
pubmed: 31719682
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484